Prevalence of abnormal glycometabolism in patients with chronic hepatitis C and related risk factors in China

Background  An epidemiologic link between hepatitis C virus (HCV) and abnormal glycometabolism had been established. This study was designed to investigate the prevalence of type 2 diabetes mellitus and insulin resistance, and to explore the relation between insulin resistance and hepatitis C virus genotype, serum hepatitis C virus-RNA level in chronic hepatitis C (CHC) patients.

Methods  Three hundred and fifty-nine consecutive patients (CHC, n=296; chronic hepatitis B (CHB), n=63) were evaluated. HCV genotyping was performed by restriction fragment method and serum hepatitis C virus-RNA quantified PCR for all CHC patients in the baseline serum. Fasting levels of insulin and glucose were measured in all patients and the homeostatic assessment of insulin resistance was calculated in the baseline serum.

Results  Type 2 diabetes mellitus was diagnosed in 15.5% of 296 CHC patients. Insulin resistance was present in 23.8% of the 235 nondiabetic CHC patients, in 23.1% of the 182 nondiabetic and noncirrhotic CHC patients, and associated with high serum HCV RNA level (OR: 1.754; 95% CI: 1.207–2.548, P=0.003) and age >40 years (OR: 3.542; 95% CI: 1.257–9.978, P=0.017). Insulin resistance was less frequent in CHB than in matched CHC (7.9% vs. 21.4% respectively, P <0.0001).

Conclusion  The incidence of insulin resistance in CHC was significantly higher than that in CHB patients, associated with high serum HCV RNA level and age >40 years.

     

快速康复外科促进术后胰岛素敏感性的恢复

Background  Few clinical studies or randomized clinical trial results have reported the impact of fast track surgery on postoperative insulin sensitivity. This study aimed to investigate the effects of fast track surgery on postoperative insulin sensitivity in patients undergoing elective open colorectal resection.

Methods  Controlled, randomized clinical trial was conducted from November 2008 to January 2009 with one-month post-discharge follow-up. Seventy patients with colorectal carcinoma requiring colorectal resection were randomized into two groups: a fast track group (35 cases) and a conventional care group (35 cases). All included patients received elective open colorectal resection with combined tracheal intubation and general anesthesia. Clinical parameters (complication rates, return of gastrointestinal function and postoperative length of stay), stress index and insulin sensitivity were evaluated in both groups perioperatively.

Results  Sixty-two patients finally completed the study, 32 cases in the fast-track group and 30 cases in the conventional care group. Our findings revealed a significantly faster recovery of postoperative insulin sensitivity on postoperative day 7 in the fast-track group than that in the conventional care group. We also found a significantly shorter length of postoperative stay and a significantly faster return of gastrointestinal function in patients undergoing fast-track rehabilitation.

Conclusion  Fast track surgery accelerates the recovery of postoperative insulin sensitivity in elective surgery for colorectal carcinoma with a shorter length of postoperative hospital stay.

     

Effect and cost of perioperative use of antibiotics in coronary artery bypass grafting: a randomized controlled study

Background  Bacterial infections remain a serious complication following coronary artery bypass grafting (CABG). The objective of the study was to determine the effectiveness of a guideline for the appropriate use of antibiotics in CABG during the perioperative period.

Methods  Six hundred and fourteen hospitalized patients who had undergone CABG from January to June 2006 were randomly allocated to an intervention group and a control group. The data on the hospital stay, days of antibiotic used, types of prophylactic antibiotics used, surgical wound infection and pulmonary infection and antibiotic costs for the patients were compared.

Results  The postoperative hospitalization days of the intervention group were significantly fewer than that for the control group (P <0.05). The time of antibiotic use and post-infection treatment time were also significantly less in the intervention group than in the control group (P <0.05). The average hospital daily cost and total cost of antibiotics were less in the intervention group than in the control group (P <0.05). Compared with the control group, prophylactic antibiotic use in the intervention group was more reasonable.

Conclusions  The guideline for the appropriate use of antibiotics in CABG during the perioperative period is effective strategies for reducing antibiotic costs, the time of antibiotic use and post-infection treatment time without compromising the patients’ clinical outcome.

     

Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study

Background  Incretin-based therapies provide additional options for treating type 2 diabetes. We aimed to evaluate the efficacy and tolerability of exenatide monotherapy in obese patients with type 2 diabetes.

Methods  A 26-week, metformin controlled, parallel-group study was conducted among antidiabetic drug-naive obese patients aged >18 years, and with type 2 diabetes. Participating patients were randomly assigned to receive exenatide or metformin treatments.

Results  Fifty-nine patients (age (50.5±8.6) years, body mass index (BMI) (30.2±1.6) kg/m², and hemoglobin A1C (HbA_1C (8.2±1.2)%) were enrolled in the study. Glucose control and weight reduction improved in both groups receiving treatment. HbA_1C and oral glucose tolerance test (OGTT) 2 hour glycemia reduction with exenatide was superior to that obtained with metformin ((–2.10±1.79)% vs. (–1.66±1.38)%, (–5.11±2.68) mmol/L vs. (–2.80±2.70) mmol/L, P <0.05). Fast plasma glucose (FPG) reduction was not significantly different between the two groups ((–1.8±2.0) mmol/L vs. (–1.6±1.7) mmol/L, P >0.05). Patients treated with exenatide achieved HbA_1C of <7% (97% of patients) and <6.5% (79%) at end-point, vs. 93% and 73% with metformin (P >0.05). Greater weight reduction was also achieved with exenatide ((–5.80±3.66) kg) than with metformin ((–3.81±1.38) kg, P <0.01). Homeostasis model assessment of beta-cell function (HOMA-B) was not significantly increased, but the insulinogenic index and HOMA for insulin sensitivity (HOMA-S) were greatly improved in the exenatide group (P <0.05). Nausea was the most common adverse effect in exenatide treatment (30% vs. 8%; P <0.05), but most cases were of mild to moderate intensity. One case in the exenatide group was withdrawn early because of severe nausea. Hypoglycemia events were often observed during the first 4 weeks, with 12% of patients in the exenatide and 3.2% in metformin groups, respectively (P <0.05). No incidents of severe hypoglycemia were reported.

Conclusions  Exenatide demonstrated more beneficial effects on HbA_1C, weight reduction and insulin resistance during 26 weeks of treatment, but there were more hypoglycemic events and mild-to-moderate nausea compared with metformin. These results suggested that exenatide monotherapy may provide a viable treatment option in newly developed type 2 diabetes.     

Primary sarcoma of the ovary: clinicopathological characteristics, prognostic factors and evaluation of therapy

Background  The primary ovarian sarcoma is a very rare malignancy. The objective of this study was to further investigate the clinicopathologic features and outcome in patients with primary sarcoma of the ovary.

Methods  Between 1988 and 2007, 24 patients with primary ovarian sarcoma who underwent treatment at Peking Union Medical Hospital were reviewed retrospectively. Response to treatment, progression and overall survival were analyzed.

Results  Patients with ovarian sarcoma had a mean age of (54.3±10.3) years, and 16 of them were postmenopausal. The most common symptom was abdominal pain, present in 14 patients. Of the 24 patients, 16 patients were pathologically diagnosed as carcinosarcoma (known as malignant mixed mesodermal tumor (MMMT)), 2 as ovarian leiomyosarcoma (LS) and 6 patients as ovarian endometrial stromal sarcoma (ESS). The patients in optimal debulking group had a median survival period of 28 months and 1-year survival rate of 71%. The patients in suboptimal debulking group had a significantly lower median survival of 6 months (P=0.02) and 1-year survival rate of 29%. Among the patients, 23 patients received chemotherapy and most of regimens were based on platinum, 3 patients received chemoradiation. The mean number of courses of combined chemotherapy was 6.6±5.0, and the response was unsatisfactory. The median survival for the entire group was 18.7 months. The one-year survival rate was 58%, and two-year survival rate only 29%.

Conclusions  Ovarian primary sarcoma has a poor overall prognosis. Optimal debulking surgery appears to be of prognostic significance. There is a clear need for further study to explore the role and the regimen of platinum-based chemotherapy in primary ovarian sarcoma.

     

Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in

Background  Both repaglinide and gliclazide are insulin secretagogues widely used in the treatment of type 2 diabetes. They stimulate insulin secretion through distinct mechanisms and may benefit patients from different aspects. The present study was to evaluate the effects of repaglinide or gliclazide on glycaemic control, insulin secretion, and lipid profiles in type 2 diabetes patients.

Methods  A total of 47 newly diagnosed type 2 diabetes patients were randomized 1:1 to receive a 4-week treatment with repaglinide or gliclazide. The standard mixed meal tolerance test was performed before and after the treatment. Plasma glucose (PG), insulin concentration, and lipid profiles were measured. The area under insulin concentration curve (AUC_ins) and the early-phase insulin secretion index (ΔI₃₀/ΔG₃₀) were calculated.

Results  After the trial, fasting and postprandial PG and postprandial insulin improved significantly in both groups (P <0.05). The maximum insulin concentration occurred earlier in the repaglinide group than that in the gliclazide group. AUC_ins increased in both groups (P <0.05), but no significant difference was found between groups. ΔI₃₀/ΔG₃₀ increased in both groups (P <0.05), especially in the repaglinide group (P <0.05). Triglyceride and total cholesterol decreased significantly in the repaglinide group in some time points, while no significant change was observed in the gliclazide group.

Conclusions  Repaglinide and gliclazide had similar effects on glycaemic control and total insulin secretion,while repaglinide had more effects on improvements in β-cell function and lipid metabolism.

     

Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention

Background  Aspirin and clopidogrel resistance plays a significant role in the development of cardiovascular ischemic events for ninety patients undergoing percutaneous coronary intervention. Recent studies have indicated that increasing the dose of antiplatelet drugs maybe a potent method to improve the inhibition of platelet aggregation.

Methods  Thrombelastograph (TEG) determinations were used to evaluate the effect of antiplatelet therapy. According to the results, 90 patients were divided into three groups and given different doses of aspirin and clopidogrel. Thirty patients with both an inhibition rate of aspirin >50% and an inhibition rate of clopidogrel >50% were defined as the control group. Sixty patients with an inhibition rate for aspirin <50% and an inhibition rate for clopidogrel <50% were defined as the resistance group. Patients in resistance group were randomly assigned to be given a routine dose (100 mg aspirin plus 75 mg clopidogrel per day, which we called a resistance plus routine dose group, R+R) and a loading dose (200 mg aspirin and 150 mg clopidogrel per day, which we called resistance plus loading dose group, R+L) of antiplatelet therapy. A 12-month follow-up was observed to examine the change of inhibition rate of antiplatelet therapy and to estimate the relationship between inhibition rate and the occurrence of cardiovascular ischemic events.

Results  After 6 months of antiplatelet therapy, the inhibition rate of aspirin in the R+L group increased from (31.4±3.7)% to (68.6±7.1)%, which was significantly higher than that in R+R group, (51.9±8.2)% (P <0.01). The inhibition rate of clopidogrel in the R+L group increased from (22.1±3.8)% to (60.2±7.4)%, which was significantly higher than in the R+R group, (45.9±4.3)% (P <0.01). The occurrence rates of cardiovascular ischemic events, stent thrombosis, recurrent unstable angina and myocardial infarction in the R+R group were 20%, 36% and 17%, respectively. Occurrence was significantly increased compared with that in the control group, 3%, 10% and 1%, respectively (P <0.01). In contrast, the occurrence rates in the R+L group (10%, 23% and 6%, respectively) were attenuated compared with those in the R+R group (P <0.01), although still higher than in the control group (P <0.01).

Conclusions  Almost all of the cardiovascular ischemic events occurred in the first six months after percutaneous coronary intervention. According to the result of TEG determinations, earlier application of a loading dose of aspirin and clopidogrel can decrease the rate of recurrent cardiovascular ischemic events.

     

Contribution of the Akt2 gene to type 2 diabetes in the Chinese Han population

Background  The Akt2 protein kinase is thought to be a key mediator of the insulin signal transduction process. Akt2 is suggested to play a role in glucose metabolism and the development or maintenance of proper adipose tissue and islet mass. In order to determine whether the Akt2 gene plays a role in the pathogenesis of type 2 diabetes characterized by insulin resistance, and to further identify if variations in this gene have a relationship with type 2 diabetes, we sequenced the entire coding region and splice junctions of Akt2 and made a further case-control study to explore the association between single-nucleotide polymorphisms (SNPs) in this gene and type 2 diabetes in the Chinese Han population.

Methods  We selected 23 probands with a type 2 diabetic pedigree whose family members’ average onset age was within 25 to 45 years old. The body mass index of all the participants was lower than 28 kg/m² and all of them were insulin-resistant (the fasting insulin level >100 pmol/L or 16 µIU/ml). The entire coding region and splice junctions of Akt2 were directly sequenced in these 23 probands. SNPs with a frequency of minor allele over 20 percent were selected to be further studied in a case-control study. We chose 743 non-diabetic subjects as the control group and 742 type 2 diabetic patients as the case group. All these subjects were genotyped. A Snapshot Technology Platform (Applied Biosystems) was used for genotyping.

Results  The Akt2 genes from all 23 subjects were successfully sequenced. We did not identify any mutation in the type 2 diabetic pedigree. Two SNPs were identified, 13010323T>C and 13007939G>T. 13010323T>C was in intron 9, which was the location of rs2304188 reported in Genbank. Its minor allele frequency was 13.04%. 13007939G>T was in the 3′-untranslated region (UTR) of exon 14, which was the location of rs2304186 reported in Genbank. Its minor allele frequency was 34.78%. The allele frequency of rs2304188 and rs2304186 were consistent with the frequency reported in Genbank. In the case-control study with 742 patients and 743 controls, there was no significant difference between the two groups for the allele frequency of rs2304186 (odd ratio: 0.96, 95% confidence interval: 0.82–1.12, P=0.597).

Conclusions  The Akt2 gene is not a major cause of diabetes in a non-obese Chinese Han population characterized by insulin resistance. There is no significant relationship between rs2304186 and type 2 diabetes in the Chinese Han population.

     

Endovascular treatment of intracranial aneurysms using coil embolization plus an Enterprise stent

Background  Several difficulties can arise from wide-neck cerebral aneurysms when treated with endovascular embolization. We aimed to investigate the effect of endovascular treatment of intracranial aneurysms using coil embolization plus an Enterprise stent.

Methods  Forty patients were treated with coil embolization plus an Enterprise stent between December 2008 and June 2010.

Results  The mortality of patients was 0. All stents were successfully implanted without any surgery-related complication.

Conclusion  The Enterprise stent has some advantages to be selected.

     

不同胰岛素增敏剂对胰岛素抵抗型PCOS患者的疗效

目的：观察二甲双胍及罗格列酮对多囊卵巢综合征（PCOS）伴有胰岛素抵抗（IR）患者内分泌的影响,评估2种药物对PCOS伴有IR的治疗价值。方法：将38例伴有IR的PCOS患者随机分为两组,一组口服二甲双胍,另一组口服罗格列酮治疗。两组用药时间均为3个月经周期,比较用药前、后体重指数、腰臀比、血清卵泡刺激素（FSH）,黄体生成素（LH）,睾酮（T）、空腹血糖（FBS）、空腹胰岛素（FIN）、胰岛素抵抗指数（HOMA．IR）的变化以及排卵率、妊娠率的改善情况。结果：罗格列酮比二甲双胍能更好地降低PCOS患者的胰岛素抵抗,但对体质量及腰臀比下降的影响不如二甲双胍。在对性激素的影响及改善排卵率、妊娠率方面两者无显著性差异。结论：二甲双胍、罗格列酮均能改善PCOS患者的胰岛素抵抗状态。二甲双胍有降低体重的作用,价格便宜;罗格列酮减轻胰岛素抵抗效果优于盐酸二甲双胍,且不良反应较小。     

两种方案治疗合并胰岛素抵抗的多囊卵巢综合征不孕患者临床疗效评价

目的:观察经达英-35联合二甲双胍或罗格列酮配合促排卵法治疗后的合并胰岛素抵抗(IR)的多囊卵巢综合征(PCOS)不孕患者的临床疗效。方法:收集近期诊治合并IR的PCOS不孕患者58例,将其随机分为A组(二甲双胍组)与B组(罗格列酮组),各29例。两种治疗均配合促排卵法,总结各组治疗前后生理指标、生化指标、内分泌水平及生殖指标的改变。结果:①治疗前后生理生化指标、内分泌水平均有明显改善(P<0.05);②两组在降低体重及胰岛素方面疗效差异有统计学意义(P<0.05);③排卵率:A组(86.11%)0.05),但B组在改善生殖功能及IR方面优于A组。而A组在降低体重方面疗效优于B组。     

胰岛素增敏剂治疗多囊卵巢综合征伴胰岛素抵抗的前瞻性研究

目的 观察在多囊卵巢综合征(PCOS)并胰岛素抵抗(IR)患者中,二甲双胍与吡格列酮联合应用及吡格列酮单独应用的临床疗效.方法 对40例PCOS并IR患者进行前瞻性研究,并选取20例非PCOS不孕妇女为对照组.PCOS组根据BMI分为A、B两组,测定糖、脂代谢指标、生殖激素及C反应蛋白(CRP)等.A组20例(吡格列酮),B组20例(二甲双胍与吡格列酮).经12周治疗后,再比较上述各指标的变化.结果 PCOS组治疗前胰岛素水平、生殖激素及CRP等均较对照组增高.2组患者治疗后胰岛素抵抗指数、甘油三脂及血清睾酮(T)等均较治疗前明显降低(P＜0.05),B组BMI较治疗前明显下降(P＜0.05).应用协方差分析治疗后2组的各指标,2hINS、T在B组下降较A组更明显(P＜0.05).结论 二甲双胍与吡格列酮联用治疗PCOS并IR,较单用吡格列酮更有效;慢性炎症反应可能参与PCOS的发生及发展过程,慢性炎症的发生可能是胰岛素敏感性降低的原因之一.     

3种方案治疗合并胰岛素抵抗的多囊卵巢综合症患者疗效研究

目的利用随机对照试验（RCT）评估PCOS患者行为治疗（锻炼及饮食控制）、二甲双肌与胰岛素增敏剂（罗格列酮）治疗的疗效,并进行疗效比较。总结3种胰岛素增敏治疗在临床的应用效果。方法将PCOS患者随机分为行为治疗、二甲双肌与罗格列酮3组,总结各组的治疗前后患者的人体学、生化、内分泌激素水平、治疗效果等观察指标并进行比较。结果 3组在治疗后的人体学、生化、激素指标无统计学差异,3组的疗效无明显差异。对3组排卵、月经情况比较,发现罗格列酮组优于行为治疗组。结论 PCOS是涉及多系统的疾病,要重视PCOS患者代谢综合征的筛查与诊治。二甲双胍,罗格列酮等胰岛素增敏治疗只造用于部分合并IR的PCOS患者,不能滥用。对PCOS患者实行个体化治疗,胰岛素增敏联合其它药物的应用,有望取得全面的治疗效果     

二甲双胍对耐克罗米酚的多囊卵巢综合征患者的临床应用

目的 了解二甲双胍对耐克罗米酚的多囊卵巢综合征（PCOS）患者的治疗作用.方法 28例耐克罗米酚PCOS患者经二甲双胍500mg每日三次治疗3个月,观察服药前后内分泌指标、体重指数（BMI）、腰臀围比值（WHR）、月经的变化及再加用克罗米酚促排卵情况.结果 二甲双胍治疗后血黄体生成素/卵泡刺激素比值（LH/FSH）、睾酮（T）、空腹胰岛素均显著降低（P＜0.05）,而BMI、WHR、空腹血糖无明显变化（P＞0.05）,同时二甲双胍治疗后21.43%患者月经恢复正常,再次用克罗米酚促排卵有13例有排卵,排卵率为46.43%,其中4例指导性生活后妊娠.结论 二甲双胍能改善耐克罗米酚PCOS患者的胰岛素抵抗及高雄激素血症,增强耐克罗米酚患者对克罗米酚的敏感性,是目前治疗PCOS新的辅助方法.     

空腹血糖受损人群干预后胰岛素抵抗与胰岛β细胞功能的改变

目的:观察空腹血糖受损者不同方法干预后的胰岛β细胞功能与胰岛素抵抗(IR)的改变情况,探讨空腹血糖受损(impaired fasting glucose,IFG)的发病机制与干预途径。方法:经葡萄糖耐量试验诊断的127例IFG随机分为3组:生活方式干预组(A组)41例,二甲双胍强化组(B组)45例,罗格列酮强化组(C组)41例。A组给予饮食和运动治疗,B组在此基础上加用二甲双胍治疗,C组加用罗格列酮治疗,在研究开始与结束时分别测量记录空腹血糖、2 h血糖、空腹胰岛素、2 h胰岛素,并在结束时复查葡萄糖耐量试验,比较各组胰岛β细胞功能与IR的改变情况。结果:A组的糖尿病转化率26.8%均高于B组和C组的6.7%与7.3%(P<0.05)。A组和B组的IR改善明显。结论:IFG的发病和IR有很大关系,二甲双胍或罗格列酮能更有效地改善IR,并减少IFG向糖尿病转化。     

二甲双胍和罗格列酮治疗多囊卵巢综合征的临床疗效观察

目的:比较二甲双胍和罗格列酮治疗胰岛素抵抗(Insulin resistance,IR)的多囊卵巢综合征(Polycystic ovarian syndrome,Pcos)患者内分泌、代谢异常的疗效.方法:将45例多囊卵巢综合征伴胰岛素抵抗的患者分为两组,A组给予罗格列酮4 m#dB组给予二甲双胍850mg/d,治疗4个月,比较治疗前后体重指数(Body mass index,BMI)、腰臀比(Waist-to-hipratio,WHR)、内分泌参数、HomaIR和血脂的变化.结果:两者治疗后,均能使血清睾酮(Testosterone,T)、黄体生成素(Luteinizing hormone,LH)、LH/FSH、空腹胰岛素(Fasting insulin,FINS)、2 h胰岛素(2 hINS)、2 h血糖(2 hPG)、低密度脂蛋白胆固醇(Low-density lipoprotein,LDL)的浓度明显下降,Homa IR明显改善(P<0.05).二甲双胍能降低BMI指数,而罗格列酮能更有效降低T、FINS、2 hINS、Homa IR.结论:罗格列酮比二甲双胍更能改善PCOS患者的胰岛素抵抗,适用于胰岛素抵抗较重的PCOS患者;二甲双胍有降低体重作用,适用于肥胖型PCOS伴胰岛素抵抗不严重者.     

二甲双胍、格列美脲对2型糖尿病患者游离脂肪酸的影响

目的：观察二甲双胍、格列美脲对2型糖尿病（T2DM）患者游离脂肪酸（FFA）的影响，并探讨T2DM中FFA与胰岛素抵抗（IR）的关系。方法：采用前瞻性、病例对照研究，将94例T2DM患者分成单用格列美脲治疗组（n =33）、单用二甲双胍治疗组（n =29）、两药合用治疗组（n=32），疗程6个月。 采用酶比色法测血清游离脂肪酸。结果：格列美脲组治疗后FFA水平无变化，二甲双胍组和两药合用组治疗后FFA水平明显下降（P＜0.05和P＜0.001)。组间比较，治疗后FFA的下降率两药合用组比格列美脲组明显(P<0.05)。多元逐步回归分析显示FFA水平与HOMA(homeostasis model assessment)胰岛素抵抗（HOMA-IR）关系密切，且FFA下降率与治疗分组有关。结论：二甲双胍单用或与格列美脲合用不仅能降低BMI，改善血糖、IR，还能降低FFA水平，且FFA水平能在一定程度上反映IR水平。     

二甲双胍治疗多囊卵巢综合征效果观察

目的:观察二甲双胍对多囊卵巢综合征(PCOS)的治疗效果.方法:选择PCOS患者24例,给予二甲双胍片1 500 mg/d,治疗6个月.检测患者治疗前、后和停药4个月的血清黄体生成素(LH)、睾酮(T)水平、口服葡萄糖耐量和胰岛素释放,观察月经变化和排卵情况.结果:二甲双胍治疗6个月后,17例(70.8%)患者恢复规律的排卵性月经.LH、T、空腹胰岛素、胰岛素曲线下面积较治疗前下降(P＜0.05),但在停药后4个月又恢复到治疗前水平(P＜0.05.停药4个月内,已恢复排卵性月经的患者又相继停经.结论:二甲双胍是一种有效的治疗PCOS的药物,但在停药后病情易于复发,提示在妊娠后应该继续应用二甲双胍治疗.     

达英-35和二甲双胍对多囊卵巢综合征患者性激素水平及胰岛素抵抗的影响

目的探讨达英-35和二甲双胍对多囊卵巢综合征（PCOS）患者性激素水平及胰岛素抵抗的影响。方法将56例PCOS患者随机分为治疗组（达英-35和二甲双胍）和对照组（达英-35）各28例,比较两组的临床症状及月经恢复情况,两组治疗前后性激素[促黄体生成素（LH）、促卵泡生成素（FSH）、睾酮（T）、雌激素（E2）]及稳态模型胰岛素抵抗指数（HOMA-IR）的变化情况,两组排卵受孕情况及不良反应。结果治疗组LH、FSH、T及HOMA-IR治疗后均较治疗前明显降低,而E2较治疗前明显升高（P〈0.05）。治疗组排卵率、受孕率均明显高于对照组（P〈0.05）,且流产率低于对照组,差异有统计学意义（P〈0.05）。结论达英-35和二甲双胍联用具有协同作用,能更有效地降低LH、T,纠正PCOS代谢紊乱,显著改善PC0S患者的内分泌况,提高排卵率和妊娠率,且胰岛素素抵抗相关指标得到明显改善,但仍需大量临床随机对照研究的进一步证实。